Policy & Regulation
Celsius Therapeutics Makes Executive Leadership Team Appointments
24 May 2019 - - US-based Celsius Therapeutics, a company translating single-cell genomic insights into precision therapeutics for patients with autoimmune diseases and cancer, has made its first key l...
Altasciences to Lead Research on Chemical Nerve Agent Therapeutic from Preclinical to Clinical Phase I
24 May 2019 - - Canadian contract research organisation Altasciences has been selected by Leidos Health to guide and support the development of RAP-103 peptide as a chemical nerve agent therapeut...
Synlogic Forges Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
24 May 2019 - - US-based clinical stage company Synlogic, Inc., (NASDAQ: SYBX) has forged a new clinical collaboration with Swiss healthcare company Roche (SIX: RO), to explore Synlogic's Sy...
Progenity Presents Proof-of-Concept Data on Proprietary Ingestible Technologies for Diagnosis, Monitoring, and Treatment of Gastrointestinal Disorders
24 May 2019 - - US-based biotechnology company Progenity, Inc has received results from three studies that represent potential breakthrough systems for diagnosing, treating, and monitoring digestive d...
Celsius Therapeutics Makes Executive Leadership Team Appointments
24 May 2019 - - US-based Celsius Therapeutics, a company translating single-cell genomic insights into precision therapeutics for patients with autoimmune diseases and cancer, has made its first key l...
Altasciences to Lead Research on Chemical Nerve Agent Therapeutic from Preclinical to Clinical Phase I
24 May 2019 - - Canadian contract research organisation Altasciences has been selected by Leidos Health to guide and support the development of RAP-103 peptide as a chemical nerve agent therapeut...